Intriguingly, early phase clinical trials attempted to employ monoclonal antibodies targeting CD40, CD27, or TIM-3 for treatment of advanced solid tumors (including HPV-related head and neck cancer), mostly in combination with PD-1/PD-L1 inhibitors35–38. This evidence concerns the gene CD274 and head and neck cancer.